Allergan Is Bullish on Biotech

Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced […]

Allergan Eyes Clinical-Stage Ocular Drugs

Allergan plc (NYSE: AGN) just purchased privately-held RetroSense Therapeutics LLC for $60 million in an all-cash transaction, with potential regulatory and commercialization milestone payments. Based in Ann Arbor Michigan, RetroSense is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in those suffering from blindness. Its lead development program, RST-001, is […]